Drugs / Viralym-C
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02313857 | Sep 2015 → May 2017 | cytomegalovirus infection | AlloVir | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Viralym-C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02313857 ↗ |
| Action | Deplete | “These peptides train a kind of white blood cell called T cells to recognize and kill cells that are infected with CMV.” NCT02313857 ↗ |
| Modality | Cell therapy | “Viralym-C cells will be thawed and injected into the intravenous line.” NCT02313857 ↗ |
| Route | Intravenous | “Partially HLA-matched Viralym-C cells will be thawed and given by intravenous injection.” NCT02313857 ↗ |